articleTop 1% cited
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
The Lancet Oncology · 2018 · Vol. 19(7) · pp. 940–952
Andrew X. Zhu✉(Massachusetts General Hospital)Richard S. Finn(University of California, Los Angeles)Julien Edeline(Centre Eugène Marquis)Stéphane Cattan(Hôpital Claude Huriez)Sadahisa Ogasawara(Chiba University)Daniel H. Palmer(University of Liverpool)Chris VerslypeVittorina Zagonel(Istituto Oncologico Veneto)Lætitia Fartoux(Sorbonne Université)Arndt Vogel(Medizinische Hochschule Hannover)Debashis Sarker(King's College Hospital)Gontran Verset(Erasmus Hospital)Stephen L. Chan(Chinese University of Hong Kong)Jennifer J. Knox(Princess Margaret Cancer Centre)Bruno Daniele(Azienda Ospedaliera G.Rummo)Andrea L. Webber(Merck & Co., Inc., Rahway, NJ, USA (United States))Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States))Junshui Ma(Merck & Co., Inc., Rahway, NJ, USA (United States))Abby B. Siegel(Merck & Co., Inc., Rahway, NJ, USA (United States))Ann‐Lii Cheng(National Taiwan University Hospital)Masatoshi Kudo(Kindai University)Angela AlistarJamil AsselahJean‐Frédéric BlancIvan BorbathTimothy Lewis CannonKi Y. ChungAllen Lee CohnDavid CosgroveNevena DamjanovMukul GuptaYoshivasu KarinoMark KarwalAndreas KaubischRobin Kate KelleyJena-Luc Van LaethemTimothy LarsonJames LeeDaneng Li(National Taiwan University Hospital)Atisha ManhasGulam A. ManjiKazushi NumataBenjamin M. ParsonsAndrew Scott PaulsonCarmine PintoRobert A. RamirezSuresh RatnamMagnus RizellOlivier RosmorducYvonne H. Sada(Chiba University)Yutaka SasakiPer StålSimone I. StrasserJoerg TrojanGina M. VaccaroHans Van VlierbergheAlan WeissKarl-Heinz WeissTatsuya Yamashita
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and BiomarkersCancer Mechanisms and TherapyMedicinePembrolizumabSorafenibInternal medicineClinical endpointHepatocellular carcinomaAdverse effectResponse Evaluation Criteria in Solid TumorsPopulationOncology
MeSH terms
SorafenibAgedDose-Response Relationship, DrugDrug Administration ScheduleFemaleCarcinoma, HepatocellularHumansInfusions, IntravenousLiver NeoplasmsMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingPrognosisRemission Induction
Funding
- Merck
Citations
2,498
FWCI
150.40
field-weighted impact
References
31
Percentile
100%
vs. same field & year
Citations per year
Cited by
Employee engagement impact on job satisfaction and employee retention
International Journal of Advanced Academic Studies · 2024 · 0 citations
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
New England Journal of Medicine · 2020 · 6,911 citations
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Cancers · 2020 · 1,166 citations
Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment
Cells · 2020 · 489 citations
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2018 · 1,047 citations
References
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
New England Journal of Medicine · 2015 · 9,308 citations
Sorafenib in Advanced Hepatocellular Carcinoma
New England Journal of Medicine · 2008 · 12,835 citations
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
The Lancet Oncology · 2008 · 5,801 citations
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
European Journal of Cancer · 2008 · 28,935 citations
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Journal of Hepatology · 2013 · 982 citations
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Biometrika · 1934 · 4,654 citations
Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
Clinical Cancer Research · 2009 · 812 citations
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2016 · 9,911 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.